Prevalence of cervical colonization by Ureaplasma parvum, Ureaplasma urealyticum , Mycoplasma hominis and Mycoplasma genitalium in childbearing age women by a commercially available multiplex real-time PCR: An Italian observational multicentre study

Leli, Christian; Mencacci, Antonella; Latino, Maria Agnese; Clerici, Pierangelo; Rassu, Mario; Perito, Stefano; Castronari, Roberto; Pistoni, Eleonora; Luciano, Eugenio; Maria, Daniela De; Morazzoni, Cristina; Pascarella, Michela; Bozza, Silvia; Sensini, Alessandra

doi:10.1016/j.jmii.2017.05.004

Cited by 69 publications

(67 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study conducted in Japan showed an Ureaplasma parvum prevalence of 41.7% in women attending their first prenatal visit [23]; another study, carried out in Slovenia, showed that significantly more women aged 25 years and younger were infected with U. urealyticum (23.4%) compared to those aged above 25 years (9.2%), irrespective of symptoms [28]. Other studies conducted in Italy have reported positivity rates for Ureaplasma parvum of almost 25% in vaginal specimens [22] and 38.3% in cervical samples [29].…”

Section: Discussionmentioning

confidence: 97%

Prevalence of Human Papillomavirus (HPV) and Other Sexually Transmitted Infections (STIs) among Italian Women Referred for a Colposcopy

Martinelli

Musumeci

Sechi

et al. 2019

IJERPH

View full text Add to dashboard Cite

Sexually transmitted infections (STIs) represent a major cause of morbidity in women and men worldwide. Human Papillomavirus (HPV) infections are among the most prevalent STIs and persistent infections with high-risk HPV (hrHPV) genotypes can cause cervical dysplasia and invasive cervical cancer. The association of other STIs with HPV cervical infection and/or dysplasia has however not yet been fully elucidated. The aim of this study was to assess the prevalence of HPV and other STIs among women presenting with an abnormal cervical cytology. Cervical infections with 28 HPV genotypes and seven other sexually transmitted pathogens were evaluated in 177 women referred for a colposcopy after an abnormal Pap smear. Positivity for at least one hrHPV genotype was shown in 87% of women; HPV 16 was the most prevalent (25.0%), followed by HPV 31 and HPV 51. The overall positivity for other STIs was 49.2%, with Ureaplasma parvum being the most prevalent microrganism (39.0%). Co-infections between hrHPV and other STIs were demonstrated in 17.5% of women; no significant association was demonstrated between multiple infections and the colposcopy findings. This study provides new epidemiological data on the prevalence of cervical infections associated with HPV and seven other common sexually transmitted pathogens in a population of women presenting with an abnormal cervical cytology.

show abstract

Section: Discussionmentioning

confidence: 97%

Prevalence of Human Papillomavirus (HPV) and Other Sexually Transmitted Infections (STIs) among Italian Women Referred for a Colposcopy

Martinelli

Musumeci

Sechi

et al. 2019

IJERPH

View full text Add to dashboard Cite

show abstract

“…The prevalence of M. hominis , U. urealyticum and U. parvum in non‐pregnant sexually active symptomatic and asymptomatic women, measured by molecular tests including species differentiation, has ranged between 3.1–15% #bib5.2–20% and 20–89%, respectively . The large variation in prevalence probably reflects both methodological and true population differences, in particular in the prevalence of BV, the most important confounder.…”

Section: Womenmentioning

confidence: 99%

“…However, both of these ureaplasmas are frequently associated with increased positivity for several traditional STIs, e.g. C. trachomatis and M. genitalium , and/or BV . The bacterial load of particularly M. hominis and to a lesser extent U. parvum and U. urealyticum can be significantly increased in the dysbiosis of BV .…”

Section: Womenmentioning

confidence: 99%

“…4,26,27,39 Women The prevalence of M. hominis, U. urealyticum and U. parvum in non-pregnant sexually active symptomatic and asymptomatic women, measured by molecular tests including species differentiation, has ranged between 3.1-15%, 5.2-20% and 20-89%, respectively. 5,[46][47][48][49][50][51][52][53][54] The large variation in prevalence probably reflects both methodological and true population differences, in particular in the prevalence of BV, the most important confounder. M. hominis and ureaplasmas can be horizontally transmitted, and although colonization tends to decrease with age until puberty, detection of these bacteria in prepubertal girls even in the absence of sexual abuse is not unusual, 55,56 which illustrates that sexual transmission is not required.…”

Section: Male Infertilitymentioning

confidence: 99%

“…C. trachomatis and M. genitalium, and/or BV. 8,46,49,59 The bacterial load of particularly M. hominis and to a lesser extent U. parvum and U. urealyticum can be significantly increased in the dysbiosis of BV. 4,48,60 However, despite the association between particularly M. hominis and BV, M. hominis cannot be detected in approximately one-third of women with BV and, accordingly, it is neither a sufficiently sensitive nor specific bacterial marker for diagnosis of BV.…”

Section: Male Infertilitymentioning

confidence: 99%

See 2 more Smart Citations

Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? – a position statement from the European STI Guidelines Editorial Board

Horner

Donders

Cusini

et al. 2018

Acad Dermatol Venereol

167

146

View full text Add to dashboard Cite

At present, we have no evidence that we are doing more good than harm detecting and subsequently treating Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum colonizations/infections. Consequently, routine testing and treatment of asymptomatic or symptomatic men and women for M. hominis, U. urealyticum and U. parvum are not recommended. Asymptomatic carriage of these bacteria is common, and the majority of individuals do not develop any disease. Although U. urealyticum has been associated with urethritis in men, it is probably not causal unless a high load is present (likely carriage in 40-80% of detected cases). The extensive testing, detection and subsequent antimicrobial treatment of these bacteria performed in some settings may result in the selection of antimicrobial resistance, in these bacteria, 'true' STI agents, as well as in the general microbiota, and substantial economic cost for society and individuals, particularly women. The commercialization of many particularly multiplex PCR assays detecting traditional non-viral STIs together with M. hominis, U. parvum and/or U. urealyticum has worsened this situation. Thus, routine screening of asymptomatic men and women or routine testing of symptomatic individuals for M. hominis, U. urealyticum and U. parvum is not recommended. If testing of men with symptomatic urethritis is undertaken, traditional STI urethritis agents such as Neisseria gonorrhoeae, Chlamydia trachomatis, M. genitalium and, in settings where relevant, Trichomonas vaginalis should be excluded prior to U. urealyticum testing and quantitative species-specific molecular diagnostic tests should be used. Only men with high U. urealyticum load should be considered for treatment; however, appropriate evidence for effective treatment regimens is lacking. In symptomatic women, bacterial vaginosis (BV) should always be tested for and treated if detected.

show abstract

Emerging role for Ureaplasma parvum serovar 3: Active infection in women with silent high‐risk human papillomavirus and in women with idiopathic infertility

Zanotta

Campisciano

Morassut

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Recently, there are controversial opinions on the presence of Mycoplasmas/Ureaplasmas as colonizers or pathogens, and on the use of a targeted therapy. This study aimed to characterize Mycoplasmas/Ureaplasmas infections in reproductive age women, including the acquisition of sexually transmitted (ST) pathogens and poor birth outcomes. A total of 646 healthy Italian women fulfilled the inclusion criteria including 521 infertile women, 65 pregnant women, and 60 fertile women with identified risk factors and symptomatic for vaginitis/cervicitis. Multiplex and quantitative molecular techniques and direct automatic DNA sequencing were performed to assess the genome structure of Mycoplasma/Ureaplasma species and ST infected pathogens. Ureaplasma parvum serovar 3 represented the predominant colonizer of the urogenital tract of this series and the unique species significantly associated with ST pathogens coinfection (p < 0.01). U. parvum load >104 bacteria/ml, suggestive of active infection, has been measured only in asymptomatic high‐risk human papillomavirus infected women (24.3%) and in 40% of women with idiopathic infertility. To note, 16% of the follicular fluid from these idiopathic women resulted infected with U. parvum. In conclusion, the present study focused the attention on U. parvum serovar 3 as emerging microorganism in sexually active women that may have the benefit of targeted therapy.

show abstract

Prevalence of cervical colonization by Ureaplasma parvum, Ureaplasma urealyticum , Mycoplasma hominis and Mycoplasma genitalium in childbearing age women by a commercially available multiplex real-time PCR: An Italian observational multicentre study

Abstract: multiplex RT-PCR can be a valuable tool to evaluate the real epidemiology of cervical mycoplasma colonization.

Cited by 69 publications

References 29 publications

Prevalence of Human Papillomavirus (HPV) and Other Sexually Transmitted Infections (STIs) among Italian Women Referred for a Colposcopy

Prevalence of Human Papillomavirus (HPV) and Other Sexually Transmitted Infections (STIs) among Italian Women Referred for a Colposcopy

Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? – a position statement from the European STI Guidelines Editorial Board

Emerging role for Ureaplasma parvum serovar 3: Active infection in women with silent high‐risk human papillomavirus and in women with idiopathic infertility

Contact Info

Product

Resources

About